Everett Vokes, MD
Everett Vokes, MD, is the John E. Ultmann Professor and in the Department of Medicine, Section of Hematology/Oncology and the Department of Radiation and Cellular Oncology at the University of Chicago Pritzker School of Medicine and is physician-in-chief and chairman of the Department of Medicine at the University of Chicago Medical Center in Chicago, Illinois, USA.
Dr. Vokes earned his medical degree at the University of Bonn Medical School in Bonn, Germany. He completed his clerkship at St Luke’s Hospital in Sydney, Australia, and an internship at Malteser Hospital in Bonn. He completed his internship and residency in internal medicine at the Ravenswood Hospital Medical Center in Chicago, a senior residency in internal medicine at the University of Southern California-Los Angeles County Hospital, and a fellowship in hematology-oncology at the University of Chicago.
A clinical and translational investigator, Dr. Vokes focuses on the biology and treatment of lung and head and neck cancers and the interaction of chemotherapy and radiation and integration of targeted and immune-based agents. He established the intellectual and clinical basis of national trials investigating concomitant chemoradiotherapy and other approaches to providing multispecialty care and leads clinical and translational investigations both at the university and nationally.
Dr. Vokes is a member of professional organizations including the American Society of Clinical Oncology, American Society for Clinical Investigation, American Association for Cancer Research, and International Association for the Study of Lung Cancer, among others. He serves on the editorial boards of several oncology journals and is a reviewer for various publications.
To his credit are more than 80 book chapters and 500 papers published in such journals as New England Journal of Medicine, Journal of Clinical Oncology, Annals of Oncology, and Journal of Thoracic Oncology, to name a few. Dr. Vokes has presented his work at numerous medical congresses.
Financial relationships
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:AbbVieTopic:Consultant/Advisory RoleDate added:12/09/2021Date updated:12/09/2021
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:AstraZenecaTopic:Consultant/Advisory RoleDate added:12/09/2021Date updated:12/09/2021
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:BeigeneTopic:Consultant/Advisory RoleDate added:12/09/2021Date updated:12/09/2021
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:BioNTechTopic:Consultant/Advisory RoleDate added:12/09/2021Date updated:12/09/2021
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:Eli LillyTopic:Consultant/Advisory RoleDate added:12/09/2021Date updated:12/09/2021
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:EMD SeronoTopic:Consultant/Advisory RoleDate added:12/09/2021Date updated:12/09/2021
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:GenentechTopic:Consultant/Advisory RoleDate added:12/09/2021Date updated:12/09/2021
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:GlaxoSmithKlineTopic:Consultant/Advisory RoleDate added:12/09/2021Date updated:12/09/2021
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:MerckTopic:Consultant/Advisory RoleDate added:12/09/2021Date updated:12/09/2021
-
Attribution:SelfType of financial relationship:Financial SupportIneligible company:NovartisTopic:Consultant/Advisory RoleDate added:12/09/2021Date updated:12/09/2021